Landbo C, Almdal T P
H:S Hvidovre Hospital, medicinsk endokrinologisk afdeling.
Ugeskr Laeger. 1998 May 25;160(22):3226-7.
Coenzyme Q10 (Ubidecarenone) is marketed as a dietary supplement. Drug interaction between coenzyme Q10 and warfarin has previously been reported. In the present case, a 72-year-old female treated with warfarin showed less responsiveness to warfarin than previously. It appeared she had taken coenzyme Q10, and when this was stopped, her responsiveness to warfarin was the same as before. Coenzyme Q10 is chemically similar to K-vitamins, which may explain the interaction with warfarin. Patients in treatment with warfarin should be aware of the possible risk of treatment failure when taking coenzyme Q10. The need for questioning patients concerning not only medications but also use of dietary supplements and alternative medications is emphasised.
辅酶Q10（泛癸利酮）作为一种膳食补充剂在市场上销售。此前已有辅酶Q10与华法林之间药物相互作用的报道。在本病例中，一名接受华法林治疗的72岁女性对华法林的反应性比之前降低。她似乎服用了辅酶Q10，当停用辅酶Q10后，她对华法林的反应性恢复到了之前的水平。辅酶Q10在化学结构上与维生素K相似，这可能解释了其与华法林之间的相互作用。接受华法林治疗的患者在服用辅酶Q10时应意识到治疗失败的潜在风险。强调不仅要询问患者所服用的药物，还要询问其膳食补充剂和替代药物的使用情况。
